Recent Progress In The Development Of Beta 2 Adrenergic Receptor Agonists: A Patent Review (2015-2020)

IntroductionThe beta(2) adrenergic receptor (beta(2)AR) is a member of G protein-coupled receptors (GPCRs) that mediate the majority of cellular responses to external stimuli. The agonists can cause smooth muscle relaxation; therefore, many beta(2)AR agonists have been developed especially for the treatment of pulmonary disorders such as asthma and chronic obstructive pulmonary disease (COPD). Many new natural and synthetic compounds have been discovered and developed as novel beta(2)AR agonists over the past 5 years.Areas coveredThis review offers an update for the development of beta(2)AR agonists in the patents published from 2015 to 2020, including new natural and synthetic compounds for the treatment of asthma and COPD. In particular, the latest patents about compounds possessing both muscarinic receptor antagonist and beta(2) adrenergic receptor agonist activity are reviewed.Expert opinionbeta(2)AR agonists have been developed extensively for the treatment of asthma and COPD. In the past 5 years, novel agonists from both natural sources and synthetic methods were intensively developed. Compounds possessing both muscarinic receptor antagonist and beta(2)AR agonist activity represent a new trend in this area because they are possibly able to act together in a synergistic fashion, therefore, relieve the symptoms of patients through two distinct mechanisms.